Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers SUPN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Revenue
Fiscal 2026
Given $840.00M to $870.00M release Feb 24, 2026
Lowered $40.00M to $50.00M release May 5, 2026
– Not reported yet
The company's words
Full year 2026 guidance for total revenues of $840 million to $870 million, operating earnings of $0 million to $30 million, and adjusted operating earnings (Non-GAAP) (1) of $140 million to $170 million. release Feb 24, 2026
Current Guidance (as of February 24, 2026) ────────────────────────────────────────────────────────────────────────────── Total revenues include the following(7): … Trokendi XR and Oxtellar XR net sales of $40 - $50 million Combined R&D and SG&A expenses $620 - $650 Operating earnings $0 - $30 Adjusted operating earnings $140 - $170 (non-GAAP)(1) release May 5, 2026
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $600.00M to $630.00M release Feb 25, 2025
$718.95M
10-K filed 2026-03-02
Above the range
The company's words
Full year 2025 guidance for total revenues of $600 million to $630 million, operating earnings (loss) of $(15) million to $10 million and adjusted operating earnings (Non-GAAP) (1) of $105 million to $130 million. release Feb 25, 2025
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $580.00M to $620.00M release Feb 27, 2024
$661.82M
10-K filed 2025-02-25
Above the range
The company's words
Full year 2024 total revenue (GAAP) guidance of $580 million to $620 million and operating earnings (non-GAAP) (3) guidance of $80 million to $110 million. release Feb 27, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (24 releases since 2024-02-13), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.